Programming in Vagus nerve stimulation therapy: Consensus from a Nordic Delphi Panel.

Purpose: Despite VNS therapy being established broadly as a second line treatment for drug resistant epilepsy, there are currently no guidelines or recommendations giving sufficient and detailed guidance and suggestions to fully utilize the increasing array of parameter options.

Methods: A panel of 22 experts from the Nordic countries (6 were pediatric neurologists, 14 neurologists and 2 treating both pediatric and adult patients) was assembled to share their experience with VNS therapy using a 5-step Delphi approach. Agreement level ≥80% was considered strong consensus and 60 to79% was considered medium consensus.

Promoting health through climate change mitigation in Europe.

Several EU climate change mitigation policies have the potential to deliver health co-benefits. However, existing frameworks guiding research in this area lack important details that are needed to understand how evidence of health co-benefits can be used to support the ambition and acceptability of EU climate policy. In this Personal View, we propose an integrated framework for advancing the state-of-the-science on health co-benefits of climate change mitigation and realising the societal effect of evidence documenting co-benefits.

[Not Available].

About 40 % of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 % seizure frequency reduction in 50-56 % of patients.

Sudden unexpected death in epilepsy in persons younger than 50 years: A retrospective nationwide cohort study in Denmark.

Objective: Persons with epilepsy have an increased mortality including a high risk of sudden unexplained death (SUD), also referred to as sudden unexpected death in epilepsy (SUDEP). We aimed to evaluate the risk of SUDEP in comparison to other causes of death and the risk of SUD in persons with and without epilepsy.

Methods: We undertook a retrospective population-based cohort study of all Danish citizens with and without epilepsy aged 1-49 years during 2007-2009.

[Todd's paralysis].

Todd's paralysis is a clinical entity consisting of acute focal neurological deficits following an epileptic seizure. It occurs after 6-13% of seizures, and the symptoms may last from minutes to 36 hours. Stroke with seizure at symptom onset is difficult to differentiate clinically from Todd's paralysis.

Somatosensory phenomena elicited by electrical stimulation of hippocampus: Insight into the ictal network.

Up to 11% of patients with mesial temporal lobe epilepsy experience somatosensory auras, although these structures do not have any somatosensory physiological representation. We present the case of a patient with left mesial temporal lobe epilepsy who had somatosensory auras on the right side of the body. Stereo-EEG recording demonstrated seizure onset in the left mesial temporal structures, with propagation to the sensory cortices, when the patient experienced the somatosensory aura.

[Epilepsy surgery].

Surgery is the only treatment option with the potential to cure epilepsy. This review is a description of the multidisciplinary and multimodal presurgical evaluation process and the outcome of the Danish epilepsy surgery programme. The outcome aligns with international results and serious complications to surgery are very rare.

[Atypical presentation of tuberous sclerosis].

Tuberous sclerosis complex (TSC) is an inherited disorder with a prevalence of 1/20,000. The diagnosis is based on clinical criteria and/or genetic testing. Most cases are found during childhood.

Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis.

Purpose: To assess adverse events with use of antiepileptic drugs (AEDs) by the method of sequence symmetry analysis.

Methods: We used data from two population-based sources in Funen County, Denmark (population 2006: 479,000); prescription data from Odense University Pharmacoepidemiological Database (OPED) for the period of 1 August 1990-31 December 2006, and diagnoses from the County Hospital register for the period of 1994-2006 to perform sequence symmetry analysis. The method assesses the distribution of disease entities and prescription of other drugs (ODs), before and after initiation of AED treatment, as asymmetry in these distributions may indicate adverse events of AED use.

Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study.

Purpose: To investigate whether the use of antiepileptic drugs (AEDs) increases the risk of hip fracture.

Methods: We performed a case-control study using data from the Funen County (population 2004: 475,000) hip fracture register. Cases (n = 7,557) were all patients admitted to county hospitals with a hip fracture during the period 1996-2004.

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study.

Most migraine patients with infrequent attacks are currently not treated with migrainespecific medication such as triptans. The response of these patients to triptans is unknown. The objective of this study was to investigate the efficacy and tolerability of sumatriptan 50 mg vs.

Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study.

Background And Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with bleeding complications and may affect the risk of hemorrhagic stroke through inhibition of platelet cyclooxygenase-1. We performed a population-based case-control study to estimate the risk of intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke in users of NSAIDs.

Methods: We used a population-based patient registry to identify all patients with a first-ever stroke discharge diagnosis in the period of 1994 to 1999.

Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study.

Background And Purpose: Selective serotonin reuptake inhibitors (SSRIs) have been associated with increased risk of bleeding complications, possibly as a result of inhibition of platelet aggregation. Little is known about the risk of intracerebral hemorrhage in users of SSRIs and whether the effect on platelet aggregation reduces the risk of ischemic stroke. We used population-based data to estimate the risk of hemorrhagic and ischemic stroke in users of SSRIs.